Details

Tech Scouting Requirements

We are seeking innovations in peptide therapeutics across the following 2 disease areas:

1.       Immunology

Technology Interests:

• Peptide Drug Conjugates: Peptide carriers conjugated to small molecules or biologically active agents for targeted immunomodulation.

• Radionuclide Peptide Conjugates: Therapeutics that combine peptide specificity with radiotherapeutic precision to treat inflammatory or autoimmune disease.

Required Stage:

• In vivo efficacy data required.

2.       Metabolic Disease, Sarcopenia

Technology Interests:

• Novel Peptide Therapeutics: New peptides that demonstrate improved safety and efficacy for treating muscle loss and functional decline in aging populations.

Desired characteristics include:

o     Extended half-life

o     Oral bioavailability

o     Time-release formulations (e.g., sustained micro-dosing tablets)

Required Stage:

• In vivo efficacy data required.

• Preferred: Supporting non-GLP or GLP toxicity data.

Problem Statement

Peptide-based therapies hold significant promises for precision treatment in both immunology and metabolic disorders. However, challenges such as short half-life, delivery limitations, and suboptimal safety profiles have hindered broad clinical adoption. Celltrion seeks to address these challenges by partnering with innovators developing differentiated peptide technologies with proven efficacy and strong translational potential.

Why Apply?

This is a compelling opportunity to collaborate with Celltrion, a biopharmaceutical leader who developed the first biosimilar with deep expertise in drug development and biologics manufacturing. Celltrion is open to worldwide partnerships beyond the APAC region, offering selected innovators access to co-development, investment, licensing, and commercialization opportunities. Join us in shaping the next wave of peptide-based treatments that can transform lives and redefine care standards.

Submissions close on 30 June

Apply now and help redefine the therapeutic potential of peptides in immunology and metabolic disease.

For inquiries, please contact startup.relations@ventureblick.com

创新具体要求

我们正在寻找以下两类疾病治疗领域的肽类创新药物：

1. 免疫疾病

技术方向：

• 肽偶联药物（PDC）：肽载体与小分子或生物活性剂偶联，用于靶向免疫调节。

• 多肽偶联放射性核素药物：将肽特异性与放射治疗的精准性相结合，用于治疗炎症或自身免疫性疾病的疗法。

阶段要求：

• 需提供体内有效性数据。

2. 代谢性疾病、肌肉减少症

技术方向：

• 新型肽疗法：开发安全性和有效性均得到提高的新型肽，用于治疗老年人的肌肉萎缩和功能衰退。

特性要求：

o     延长半衰期

o     口服生物利用度

o     缓释制剂（例如，缓释微剂量片剂）

阶段要求：

• 需提供体内有效性数据。

• 优先考虑：有非GLP或GLP毒性试验数据。

当前挑战

肽类疗法拥有精准治疗免疫性和代谢性疾病的巨大潜力，但诸如半衰期短、给药受限、安全性欠佳等缺陷阻碍了其在临床上的广泛应用。Celltrion 致力于通过创新合作，开发具有明确的有效性和强大的转化潜力的差异化肽类技术来应对这些挑战。

为何申请？

这是与领先的生物制药跨国公司 Celltrion 合作的一个绝佳机会。Celltrion 是世界上首个单克隆抗体生物类似药的开发者，拥有药物开发和生物制剂生产的深厚能力。Celltrion 积极在亚太地区乃至全球探索合作，将为其选择的创新伙伴提供共同开发、投资、许可和商业化的多种潜在机会。与我们携手，塑造下一代肽类药物疗法，刷新护理标准并点亮生命希望。

申请提交截止日：6 月 30 日

立即申请，提升肽类创新药在免疫性和代谢性疾病治疗中的临床潜力。

如需咨询更多信息，请发送邮件至 startup.relations@ventureblick.com